2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆
Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks A, Villagrasa P, Javierre G, Sanfeliu E, Galván P, Paré L, Anderson L, Perou C, Parker J, Vivancos A, DiLullo M, Pernas S, Winer E, Overmoyer B, Mittendorf E, Bueno-Muiño C, Martín M, Prat A, Tolaney S. HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆. ESMO Open 2025, 10: 104100. PMID: 39826476, DOI: 10.1016/j.esmoop.2024.104100.Peer-Reviewed Original ResearchHER2-positive inflammatory breast cancerPathological complete responseInflammatory breast cancerNeoadjuvant systemic therapyNon-IBCBreast cancerSystemic therapyEarly-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancerPredictors of pathologic complete responseHuman epidermal growth factor receptor 2 (HER2)-positive breast cancerIBC cohortIBC statusPathologic complete response rateLow axillary burdenNoninflammatory breast cancerTrastuzumab-based chemotherapyTreatment de-escalationPhase II trialClinical-pathological featuresLong-term prognosisPCR scoreAxillary burdenNeoadjuvant trastuzumabPCR rateComplete response
2023
12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial
Lynce F, Brasó-Maristany F, Waks A, Gonzalez P, Villacampa G, Torres E, Galván P, Brunet L, Anderson L, Perou C, Parker J, Vivancos A, Dilullo M, Simon S, Winer E, Overmoyer B, Mittendorf E, Prat A, Tolaney S. 12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial. ESMO Open 2023, 8: 101236. DOI: 10.1016/j.esmoop.2023.101236.Peer-Reviewed Original ResearchInflammatory breast cancerHER2-positive inflammatory breast cancerPhase II clinical trialClinical trialsBreast cancerCorrelative analysisCancerTrials